Dr. Manax-Rutson Brings Broad Industry Expertise to Duo’s Board
Oncology executive and Eckuity Capital partner joins Duo Oncology’s board as company prepares for clinical-stage growth
PITTSBURGH (PRWEB) December 11, 2025 – Duo Oncology, a clinical-stage biotechnology company advancing ultrasmall nanomedicines that deliver dual-modality chemotherapy in a single infusion, today announced the appointment of Dr. Victoria G. Manax-Rutson, General Partner at Eckuity Capital, to its Board of Directors. A leading oncology strategist and healthcare investor, Dr. Manax-Rutson brings a unique blend of healthcare expertise and strategic industry insight as Duo prepares for its first-in-human clinical trials.
As a pharmaceutical industry leader and venture fund partner, Dr. Manax-Rutson has guided capital deployment across biotech and MedTech platforms, helping companies secure resources, scale operations, and navigate regulatory milestones. She has led transformative programs in oncology and precision medicine, positioning portfolio companies for both clinical and commercial success.
“Victoria has been instrumental in shaping Duo’s clinical roadmap,” said Dr. Sam Rothstein, Chief Executive Officer of Duo Oncology. “Her experience in building adaptive trials, strategizing oncology indications, and navigating early-stage investment landscapes brings rare strategic alignment as we prepare to enter the clinic. Her dual perspective as a medical leader and private equity partner makes her a tremendous asset to Duo Oncology.”
Dr. Manax Rutson has held leadership and executive roles in multiple biotech startups as well as at Celgene, and the Pancreatic Cancer Action Network, where she launched Precision Promise, the first adaptive Phase III clinical trial platform for pancreatic cancer. She also serves on multiple company boards and holds patents in oncology therapeutics including methods of treating biliary cancer. Her clinical development work spans Phase I–IV programs, regulatory filings, and commercialization strategies across solid tumors including GI, lung, and breast cancers.
“I am honored to serve on the Board of Duo Oncology and to contribute to its continued growth and development,” said Dr. Manax Rutson. “As a healthcare investor, I see tremendous potential in Duo’s nanomedicine platform to redefine chemotherapy. My focus will be on ensuring the company has the strategic capital, partnerships, and investor alignment needed to bring these innovations to patients.”
